146 related articles for article (PubMed ID: 22176844)
1. Biopsy follow-up of prostate-specific antigen tests.
Zeliadt SB; Buist DS; Reid RJ; Grossman DC; Ma J; Etzioni R
Am J Prev Med; 2012 Jan; 42(1):37-43. PubMed ID: 22176844
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
3. Perception of abnormal serum prostate-specific antigen (PSA) test results amongst family practitioners.
Rochester MA; Donaldson PJ; McLoughlin J
Ann R Coll Surg Engl; 2008 Jul; 90(5):398-402. PubMed ID: 18634736
[TBL] [Abstract][Full Text] [Related]
4. Lowering the PSA threshold for prostate biopsy from 4 to 2.5 ng/ml: influence on cancer characteristics and number of men needed to biopt.
Müntener M; Kunz U; Eichler K; Puhan M; Schmid DM; Sulser T; Strebel RT
Urol Int; 2010; 84(2):141-6. PubMed ID: 20215816
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen testing practices and outcomes.
Hoffman RM; Blume P; Gilliland F
J Gen Intern Med; 1998 Feb; 13(2):106-10. PubMed ID: 9502370
[TBL] [Abstract][Full Text] [Related]
7. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
Nordström T; Adolfsson J; Grönberg H; Eklund M
BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
[TBL] [Abstract][Full Text] [Related]
8. Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population?
O'Kelly F; Thomas A; Murray D; Galvin D; Mulvin D; Quinlan DM
Prostate; 2013 Sep; 73(12):1263-9. PubMed ID: 23657938
[TBL] [Abstract][Full Text] [Related]
9. What happens after an elevated PSA test: the experience of 13,591 veterans.
Zeliadt SB; Hoffman RM; Etzioni R; Ginger VA; Lin DW
J Gen Intern Med; 2010 Nov; 25(11):1205-10. PubMed ID: 20697965
[TBL] [Abstract][Full Text] [Related]
10. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
[TBL] [Abstract][Full Text] [Related]
11. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Vickers AJ; Till C; Tangen CM; Lilja H; Thompson IM
J Natl Cancer Inst; 2011 Mar; 103(6):462-9. PubMed ID: 21350221
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
[TBL] [Abstract][Full Text] [Related]
13. The effect of lowering the prostate-specific antigen normal cutoff on referral rates to urology.
Shenker BS; Stern J
J Am Board Fam Med; 2012; 25(6):927-9. PubMed ID: 23136335
[TBL] [Abstract][Full Text] [Related]
14. Abnormal PSA tests--delays in referral.
Stapleton AM; Johns RL; Kopsaftis T; Tamblyn DJ; Pinnock CB
Aust Fam Physician; 2008; 37(1-2):84-8. PubMed ID: 18239761
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
16. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.
Eastham JA; Riedel E; Scardino PT; Shike M; Fleisher M; Schatzkin A; Lanza E; Latkany L; Begg CB;
JAMA; 2003 May; 289(20):2695-700. PubMed ID: 12771116
[TBL] [Abstract][Full Text] [Related]
17. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
[TBL] [Abstract][Full Text] [Related]
18. Delays in prostate cancer care within a hospital network in Victoria, Australia.
Qu LG; Nzenza T; McMillan K; Sengupta S
ANZ J Surg; 2019 Dec; 89(12):1599-1604. PubMed ID: 31786815
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of transrectal ultrasound-guided prostate biopsy in men younger than 50 years old with an elevated prostate-specific antigen concentration (>4.0 ng/mL).
Lu CH; Lin TP; Shen SH; Huang YH; Chung HJ; Kuo JY; Huang WJS; Wu HHH; Chang YH; Lin ATL; Chen KK
J Chin Med Assoc; 2017 Jul; 80(7):413-418. PubMed ID: 28529023
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels.
Roehrborn CG; Pickens GJ; Sanders JS
Urology; 1996 Mar; 47(3):347-52. PubMed ID: 8633400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
